Dipartimento di Scienze Cliniche e, Biologiche Università di Torino, Ospedale S. Luigi, Regione Gonzole, 10, 10043, Orbassano, TO, Italy.
Basic Res Cardiol. 2014 Jul;109(4):418. doi: 10.1007/s00395-014-0418-9. Epub 2014 May 25.
Melusin is a muscle-specific protein which interacts with β1 integrin cytoplasmic domain and acts as chaperone protein. Its overexpression induces improved resistance to cardiac overload delaying left ventricle dilation and reducing the occurrence of heart failure. Here, we investigated possible protective effect of melusin overexpression against acute ischemia/reperfusion (I/R) injury with or without Postconditioning cardioprotective maneuvers. Melusin transgenic (Mel-TG) mice hearts were subjected to 30-min global ischemia followed by 60-min reperfusion. Interestingly, infarct size was reduced in Mel-TG mice hearts compared to wild-type (WT) hearts (40.3 ± 3.5 % Mel-TG vs. 59.5 ± 3.8 % WT hearts; n = 11 animals/group; P < 0.05). The melusin protective effect was also demonstrated by measuring LDH release, which was 50 % lower in Mel-TG compared to WT. Mel-TG hearts had a higher baseline level of AKT, ERK1/2 and GSK3β phosphorylation, and displayed increased phospho-kinases level after I/R compared to WT mice. Post-ischemic Mel-TG hearts displayed also increased levels of the anti-apoptotic factor phospho-BAD. Importantly, pharmacological inhibition of PI3K/AKT (Wortmannin) and ERK1/2 (U0126) pathways abrogated the melusin protective effect. Notably, HSP90, a chaperone known to protect heart from I/R injury, showed high levels of expression in the heart of Mel-TG mice suggesting a possible collaboration of this molecule with AKT/ERK/GSK3β pathways in the melusin-induced protection. Postconditioning, known to activate AKT/ERK/GSK3β pathways, significantly reduced IS and LDH release in WT hearts, but had no additive protective effects in Mel-TG hearts. These findings implicate melusin as an enhancer of AKT and ERK pathways and as a novel player in cardioprotection from I/R injury.
梅尔辛是一种肌肉特异性蛋白,可与β1 整合素胞质结构域相互作用,并充当伴侣蛋白。其过表达可诱导对心脏超负荷的抗性增强,从而延迟左心室扩张并减少心力衰竭的发生。在这里,我们研究了过表达梅尔辛对急性缺血/再灌注(I/R)损伤的可能保护作用,以及是否存在后处理的心脏保护作用。梅尔辛转基因(Mel-TG)小鼠心脏经历 30 分钟的全局缺血,随后进行 60 分钟的再灌注。有趣的是,与野生型(WT)心脏相比,Mel-TG 小鼠心脏的梗死面积减小(40.3 ± 3.5% Mel-TG 与 59.5 ± 3.8% WT 心脏;n = 11 只动物/组;P < 0.05)。通过测量 LDH 释放也证明了梅尔辛的保护作用,Mel-TG 比 WT 降低了 50%。与 WT 相比,Mel-TG 心脏的 AKT、ERK1/2 和 GSK3β 磷酸化的基线水平更高,并且与 WT 小鼠相比,在 I/R 后显示出更高的磷酸激酶水平。缺血后 Mel-TG 心脏还显示出更高水平的抗凋亡因子磷酸化 BAD。重要的是,PI3K/AKT(wortmannin)和 ERK1/2(U0126)途径的药理学抑制消除了梅尔辛的保护作用。值得注意的是,HSP90,一种已知可保护心脏免受 I/R 损伤的伴侣蛋白,在 Mel-TG 小鼠的心脏中表达水平较高,这表明该分子与 AKT/ERK/GSK3β 途径在梅尔辛诱导的保护作用中可能存在协作。后处理,已知可激活 AKT/ERK/GSK3β 途径,可显著减少 WT 心脏的 IS 和 LDH 释放,但在 Mel-TG 心脏中没有额外的保护作用。这些发现表明梅尔辛作为 AKT 和 ERK 途径的增强剂,以及作为 I/R 损伤后心脏保护的新成员。